Benzinga | Jan 26, 2021 07:09AM EST

Eloxx Pharma Highlights Publication Of Scientific Manuscript On ELX-02 In Journal Of Clinical Pharmacology In Drug Development

Eloxx Pharmaceuticals, Inc., (NASDAQ:ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis and other diseases caused by nonsense mutations limiting production of functional proteins, today announced that a scientific manuscript titled: "A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of ELX-02 in Healthy Subjects" was published in the Journal of Clinical Pharmacology in Drug Development.

"We are very pleased that our scientific manuscript on the results of our Phase 1B multiple-ascending dose trial evaluating the safety and pharmacokinetics of ELX-02 in healthy volunteers has been published in the Journal of Clinical Pharmacology in Drug Development," said Dr. Matthew Goddeeris, PhD, Vice President of Research, Eloxx Pharmaceuticals. "There were no severe or serious adverse events reported in the trial, which is consistent with the favorable tolerability profile demonstrated across our preclinical and clinical datasets. These data support our current Phase 2 clinical trial for ELX-02 in cystic fibrosis patients with nonsense alleles, for whom there are few, if any, treatment options available. We look forward to reporting top line data in the first half of 2021."